MONISTAT® cures just as effectively

Miconazole, the active ingredient in MONISTAT®, is just as effective at curing vulvovaginal candidiasis (VVC) as fluconazole, the leading prescription pill.1

In a clinical study comparing MONISTAT® 7 to prescription fluconazole, there was no statistically significant difference in clinical cure rates at 14 days post-treatment.1

Monistat® vs Fluconazole VVC Treatment Study

MONISTAT® relieves symptoms 4x faster*

Systemic fluconazole needs to be digested and absorbed into the bloodstream before it can begin to work. MONISTAT® begins to work on contact, curing VVC just as effectively as fluconazole while relieving symptoms much sooner.1


MONISTAT® treats more types of yeast2†

MONISTAT® is effective for both albicans and non-albicans species of yeast, and treats a broader spectrum of VVC than prescription fluconazole.


MONISTAT® MAY BE MORE APPROPRIATE FOR YOUR PREGNANT AND DIABETIC PATIENTS2,7-13‡

PREGNANCY: MONISTAT® 7 meets CDC Guidelines for treating VVC in pregnant women:2

  • Only topical azole therapies, applied for 7 days, are recommended for use among pregnant women2
 

In pregnancy, even a single, low dose of fluconazole may increase miscarriage risk.7

A nationwide cohort study in Denmark reports that pregnant women taking one or two fluconazole 150 mg doses from 7 through 22 weeks gestation may be at significantly higher risk of miscarriage.7

This study informed a 2016 FDA Drug Safety Communication:8

  • Pregnant women and women trying to get pregnant should discuss alternative treatment options to fluconazole with their healthcare professionals8

The FDA is reviewing the study results and other data before making a final recommendation.

Awareness of the Danish study may be limited. In a recent survey, 57% of OB/GYNs said they prescribe fluconazole during some or all trimesters of pregnancy.14

  • For patients who are pregnant or plan to become pregnant, recommend MONISTAT® 7 for vaginal yeast infection2,8

DIABETES:
For women with diabetes, vaginal yeast infections are more likely to be caused by a non-albicans species.2,9,10

  • For non-albicans VVC, CDC Guidelines suggest a longer duration of therapy (7-14 days) with a nonfluconazole azole regimen as first-line therapy2

MONISTAT® 7 meets the CDC Guidelines for treating non-albicans VVC.

Fluconazole may increase the risk of serious hypoglycemic episodes for women on certain antidiabetic drugs.11,12

  • Fluconazole can interact with sulfonylureas (commonly used oral hypoglycemic drugs), which can increase drug plasma levels and lead to clinically dangerous episodes of hypoglycemia11-13

In a recent survey, 73% of OB/GYNs said they recommend fluconazole for vaginal yeast infection in women with diabetes more than butoconazole, miconazole, or terconazole.15 The prevalence of non-albicans species and potential drug interactions may warrant closer attention to VVC in patients with diabetes.

For vaginal yeast infection in patients with diabetes, recommend MONISTAT® 7.


*Based on a clinical study with MONISTAT® 1 Combination Pack Ovule® treatment vs the leading prescription product.
†Per 2015 CDC Guidelines, options for first-line therapy of non-albicans vulvovaginal candidiasis (VVC) include longer duration therapy (7-14 days) with a nonfluconazole azole regimen.
‡2015 CDC Guidelines recommend the use of 7-day topical azole therapies for treatment of vulvovaginal candidiasis (VVC) in pregnant women.